Becton, Dickinson and Company $BDX Shares Acquired by Swiss National Bank

Swiss National Bank raised its position in Becton, Dickinson and Company (NYSE:BDX) by 6.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 836,502 shares of the medical instruments supplier’s stock after buying an additional 51,000 shares during the period. Swiss National Bank’s holdings in Becton, Dickinson and Company were worth $131,523,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Empowered Funds LLC lifted its stake in Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after purchasing an additional 1,354 shares during the last quarter. United Bank boosted its holdings in Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 993 shares during the period. Marshall Wace LLP increased its stake in Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock valued at $5,491,000 after purchasing an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 34.7% during the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 5,188 shares of company stock worth $765,120. 0.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BDX shares. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. TD Cowen cut their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. Finally, Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $180.29.

Becton, Dickinson and Company Stock Down 2.3%

Becton, Dickinson and Company stock opened at $154.46 on Tuesday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The stock has a market cap of $42.56 billion, a price-to-earnings ratio of 39.10, a PEG ratio of 11.19 and a beta of 0.21. The company’s 50-day moving average price is $149.22 and its two-hundred day moving average price is $165.89. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the previous year, the business earned $3.35 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.